Theodore R. Schroeder - 06 Feb 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
06 Feb 2022
Net transactions value
-$126
Form type
4
Filing time
08 Feb 2022, 15:25:48 UTC
Previous filing
01 Feb 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability $126 -263 -0.08% $0.4800 314,348 06 Feb 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.